{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T16:14:42Z","timestamp":1775060082253,"version":"3.50.1"},"reference-count":31,"publisher":"Spandidos Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2025.15349","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:51:48Z","timestamp":1761043908000},"page":"1-8","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of the efficacy and prognostic factors of gemcitabine combined with oxaliplatin in non\u2011Hodgkin lymphoma"],"prefix":"10.3892","volume":"30","author":[{"given":"Xiaobo","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinqian","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xi'an Central Hospital\/Xi'an Institute of Hematology, Xi'an, Shaanxi 710000, P.R.\u00a0China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"key20251111104028_b1-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/medsci9010005","article-title":"Epidemiology of non-Hodgkin's lymphoma","volume":"9","author":"Thandra","year":"2021","journal-title":"Med Sci (Basel)"},{"key":"key20251111104028_b2-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1053\/j.semnuclmed.2022.11.001","article-title":"PET\/CT in non-Hodgkin lymphoma: An Update","volume":"53","author":"Zanoni","year":"2023","journal-title":"Semin Nucl Med"},{"key":"key20251111104028_b3-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00428-022-03432-2","article-title":"Follicular lymphoma and marginal zone lymphoma: how many diseases?","volume":"482","author":"Laurent","year":"2023","journal-title":"Virchows Arch"},{"key":"key20251111104028_b4-ol-30-6-15349","first-page":"206","article-title":"Current treatments in marginal zone lymphoma","volume":"36","author":"Alderuccio","year":"2022","journal-title":"Oncology (Williston Park)"},{"key":"key20251111104028_b5-ol-30-6-15349","first-page":"1852","article-title":"Review of lymphoma in the duodenum: An update of diagnosis and management","volume":"29","author":"Iwamuro","year":"2023","journal-title":"Virchows Arch"},{"key":"key20251111104028_b6-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00428-022-03421-5","article-title":"Recent advances in cutaneous lymphoma-implications for current and future classifications","volume":"482","author":"Goodlad","year":"2023","journal-title":"Virchows Arch"},{"key":"key20251111104028_b7-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"key":"key20251111104028_b8-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"e30214","DOI":"10.1002\/pbc.30214","article-title":"Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy","volume":"70","author":"Bender","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"key20251111104028_b9-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1016\/S2352-3026(24)00066-8","article-title":"First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer\/T cell lymphoma (SPIRIT): A multicentre, single-arm, phase 2 trial","volume":"11","author":"Tian","year":"2024","journal-title":"Lancet Haematol"},{"key":"key20251111104028_b10-ol-30-6-15349","first-page":"309","article-title":"CAR T-cell therapy for relapsed\/refractory non-Hodgkin's lymphoma: A comprehensive review","volume":"20","author":"St-Pierre","year":"2022","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20251111104028_b11-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.3390\/cells12242855","article-title":"Autologous stem cell transplant in Hodgkin's and Non-Hodgkin's lymphoma, multiple myeloma, and AL amyloidosis","volume":"12","author":"Alnasser","year":"2023","journal-title":"Cells"},{"key":"key20251111104028_b12-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"key20251111104028_b13-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41598-018-38190-2","article-title":"In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells","volume":"9","author":"Gravett","year":"2019","journal-title":"Sci Rep"},{"key":"key20251111104028_b14-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"key20251111104028_b15-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"e26110","DOI":"10.1097\/MD.0000000000026110","article-title":"Primary biliary non-Hodgkin's lymphoma: A case report","volume":"100","author":"Wu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"key20251111104028_b16-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"231","DOI":"10.11604\/pamj.2022.41.231.33778","article-title":"Primary extra-nodal non-Hodgkin's lymphoma affecting mandibular bone: A case report","volume":"41","author":"Gante","year":"2022","journal-title":"Pan Afr Med J"},{"key":"key20251111104028_b17-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"key20251111104028_b18-ol-30-6-15349","first-page":"732","article-title":"Diagnosis of non-Hodgkin's lymphoma due to a tiny polyp in the cecum","volume":"115","author":"Argum\u00e1nez Tello","year":"2023","journal-title":"Rev Esp Enferm Dig"},{"key":"key20251111104028_b19-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.21037\/jgo-24-560","article-title":"LDHA as a predictive biomarker and its association with the infiltration of immune cells in pancreatic adenocarcinoma","volume":"15","author":"Zheng","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"key20251111104028_b20-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s13277-014-2817-9","article-title":"Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer","volume":"36","author":"Tas","year":"2015","journal-title":"Tumour Biol"},{"key":"key20251111104028_b21-ol-30-6-15349","first-page":"122","article-title":"Non-Hodgkin's lymphoma with intraspinal involvement mimics bilateral thoracolumbar plexopath","volume":"32","author":"Lin","year":"2023","journal-title":"Acta Neurol Taiwan"},{"key":"key20251111104028_b22-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1177\/10781552221137700","article-title":"Non-Hodgkin's lymphoma developed during imatinib mesylate treatment of chronic myeloid leukemia","volume":"29","author":"Kassar","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"key20251111104028_b23-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"23247096211014689","DOI":"10.1177\/23247096211014689","article-title":"Non-Hodgkin's plasmablastic lymphoma as initial presentation of human immunodeficiency virus","volume":"9","author":"Jariwal","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"key20251111104028_b24-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.diabet.2019.04.006","article-title":"Association between type 1 and type 2 diabetes and risk of non-Hodgkin's lymphoma: A meta-analysis of cohort studies","volume":"46","author":"Wang","year":"2020","journal-title":"Diabetes Metab"},{"key":"key20251111104028_b25-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: A real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"key20251111104028_b26-ol-30-6-15349","first-page":"1279","article-title":"Oxaliplatin inhibits the EGFR-MAPK pathway to promote apoptosis in HCT116 cells","volume":"38","author":"Cui","year":"2022","journal-title":"Chin Pharmacol Bull"},{"key":"key20251111104028_b27-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12964-022-00974-5","article-title":"RRP9 promotes gemcitabine resistance in pancreatic cancer via activating AKT signaling pathway","volume":"20","author":"Zhang","year":"2022","journal-title":"Cell Commun Signal"},{"key":"key20251111104028_b28-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1002\/hon.3052","article-title":"Dual epigenetic agents plus rituximab-gemcitabine-oxaliplatin as salvage treatment in relapsed\/refractory diffuse large B-cell lymphoma patients failure of salvage chemotherapy","volume":"40","author":"Qu","year":"2022","journal-title":"Hematol Oncol"},{"key":"key20251111104028_b29-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/ijc.33202","article-title":"The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial","volume":"148","author":"Roider","year":"2021","journal-title":"Int J Cancer"},{"key":"key20251111104028_b30-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"7","DOI":"10.14302\/issn.2372-6601.jhor-17-1473","article-title":"Increased level of lactate dehydrogenase correlates with disease growth in Algerian children with lymphoma","volume":"2","author":"Galleze","year":"2017","journal-title":"J Hematol Oncol Res"},{"key":"key20251111104028_b31-ol-30-6-15349","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.3390\/cancers12113099","article-title":"Transforming growth factor-\u03b2: A multifunctional regulator of cancer immunity","volume":"12","author":"Xue","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T08:40:32Z","timestamp":1762850432000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2025.15349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,10,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2025.15349","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]}}}